Skip to NavigationSkip to content

acquisitions

Bayer buys BlueRock Therapeutics for $600 million

Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 million.

BlueRock is a privately held biotech focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology using a proprietary induced pluripotent stem cell (iPSC) platform.  The firm’s lead programme in Parkinson’s disease is expected to enter the clinic by the end of 2019.

Scottish borders-based Ryboquinn acquires viral delivery comany Nanogenics

The Scottish biotech company Ryboquinn has acquired English partner Nanogenics Solutions in a deal worth £4.45 million.

The Selkirk-based firm will merge with Nanogenics Solutions to form Nanogenics Limited. The new company promises to “revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy.”

Takeda reportedly sets $15bn on US acquisitions

Takeda Pharmaceuticals is reportedly willing to spend as much as $15 billion on acquisitions in the US in efforts to expand its business, the Financial Times has reported.

It has not been determined whether the sizeable pool of funds will be used in one single acquisition or several smaller purchases.  

MSD to acquire Scottish firm IOmet Pharma

MSD logo

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development of new immuno-oncology treatments for cancer.

Financial terms for the deal have not been made public, but IOMet is known to focus on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism. The firm was established in 2008, and has shareholders including the Scottish Investment Bank.

Alliance Pharma buys Sinclair’s healthcare products business for £132m

Alliance Pharma logo

Alliance has completed a £132 million purchase of Sinclair IS Pharma’s non-aesthetics healthcare business as it moves to strengthen its dermatology portfolio. 

Alliance says the deal will “significantly increase [its] footprint outside of the UK and will provide an enhanced platform for further corporate development.” 

The Wiltshire, UK-based company adds 27 products with the acquisition, including scar treatments Kelo-Cote and Flammacerium, the ulcer relief product Aloclair, stretch-mark treatment Kelo-stretch and atopic dermatitis cream Atopiclair. 

AstraZeneca to buy majority share in Acerta Pharma

AZ sign
AZ chief executive Pascal Soriot says the deal reflects the company's move to targeted business development

Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer of cancer drugs, for up to $7 billion.

AstraZeneca had earlier confirmed it was ‘exploring potential strategic options with Averta’ and has now agreed a final deal. The package will see AstraZeneca acquire 55% ownership of Acerta for an initial $4 billion in cash – with $2.5 billion to be paid at closing and $1.5 billion due before December 2018.

AstraZeneca in $5bn Acerta buyout talks

AZ building

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion (£3 billion).

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion (£3 billion).

Five benefits and challenges of the Pfizer/Allergan mega-merger

Published on 07/12/15 at 10:26am
Pfizer CEO Ian Read
Pfizer chief executive Ian Read will remain at the helm of the new company - for now

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, and what are the risks?

Positives

Tax inversion

Controversial or not, moving its tax domicile from the US to Ireland is expected to allow Pfizer to cut its tax bill from around 26% to 17 or 18%. This should free up significant funds for investment into the business.

Growth boost

Teva strips $1 billion worth of assets to clear Allergan deal

Teva image

Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan’s generic drugs business.

The deal between Teva and Allergan has been seen as a potentially antitrust arrangement due to the overlap in the two companies' drug portfolios. Before the deal, Allergan received an order from the antitrust division of the Department of Justice related to the pricing of its generic products.

Merck KGaA completes $17bn Sigma-Aldrich acquisition

Merck

Merck KGaA has announced the completion of its $17 billion acquisition of Sigma-Aldrich, having cleared the final regulatory hurdle and received European Commission approval.

Sigma-Aldrich’s board originally approved the transaction in September 2014, but Merck had to wait for its new acquisition to sell parts of its solvents and inorganics business in Europe - to industrial group Honeywell for around €105 million - before the deal could be formally completed.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches